Forty51 Ventures

Founded in 2022, Forty51 Ventures is a venture capital firm headquartered in Basel, Switzerland. It focuses on building and investing in early-stage biotechnology companies across Europe.

Tamas Schweighoffer Ph.D

Co-Founder and Partner

4 past transactions

Allegria Therapeutics

Seed Round in 2024
Allegria Therapeutics is a biotechnology company dedicated to improving the treatment landscape for therapeutics. It specializes in research and development focused on mast cells as mediators of allergy and inflammatory diseases, aiming to enhance patients' quality of life.

Mysthera Therapeutics

Seed Round in 2023
Mysthera Therapeutics is a preclinical-stage biotechnology company focused on developing innovative oral therapeutics for autoimmune diseases. The company aims to reshape the treatment landscape by addressing conditions such as glomerulonephritis, rheumatoid arthritis, and inflammatory bowel disease. Mysthera Therapeutics utilizes a unique approach that involves the inhibition of PIM kinases, which allows for the selective modulation of immune cell function across multiple lineages involved in complex autoimmune disorders. By doing so, the company seeks to provide effective treatments for significant unmet medical needs in this area.

Mosanna Therapeutics

Seed Round in 2023
Mosanna Therapeutics is a biotechnology company based in Basel that focuses on improving patient outcomes and quality of life for individuals with high unmet medical needs. The company employs a precision medicine approach, specializing in the development of medicinal nasal sprays. Mosanna carefully selects innovative medicines for further development and collaborates with leading contract research organizations to ensure expertise in specialized fields. This strategy enables hospitals and doctors to effectively treat patients suffering from various diseases.

Mosanna Therapeutics

Seed Round in 2022
Mosanna Therapeutics is a biotechnology company based in Basel that focuses on improving patient outcomes and quality of life for individuals with high unmet medical needs. The company employs a precision medicine approach, specializing in the development of medicinal nasal sprays. Mosanna carefully selects innovative medicines for further development and collaborates with leading contract research organizations to ensure expertise in specialized fields. This strategy enables hospitals and doctors to effectively treat patients suffering from various diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.